Galderma's Restylane Volyme Shows Strong Efficacy in Chinese Temple Hollowing Study
Event summary
- Galderma's Restylane Volyme demonstrated 94.4% effectiveness in correcting temple hollowing in 162 Chinese patients.
- 91.3% of patients showed improvement at 12 months, with over 84% satisfied with natural-looking results.
- No treatment-related serious adverse events reported, reinforcing safety profile.
- Study supports Galderma's expansion strategy in China's fast-growing aesthetics market.
The big picture
Galderma's successful study positions it to capitalize on China's booming aesthetics market, where hyaluronic acid fillers are among the top-selling products. The results address a growing demand for treatments addressing temple hollowing, particularly among patients experiencing medication-driven weight loss. This strategic move reinforces Galderma's leadership in injectable aesthetics, leveraging clinical evidence to expand its portfolio in a key growth region.
What we're watching
- Market Expansion
- Whether Galderma can sustain growth in China's competitive aesthetics market through evidence-based solutions.
- Regulatory Dynamics
- The pace at which Chinese regulators approve expanded indications for Restylane Volyme.
- Competitive Positioning
- How Galderma differentiates Restylane Volyme amid rising demand for temple hollowing treatments.